Paul Rutgeerts
Overview
Explore the profile of Paul Rutgeerts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
352
Citations
32381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riviere P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, Denost Q, et al.
Clin Gastroenterol Hepatol
. 2020 Apr;
19(4):713-720.e1.
PMID: 32272248
Background & Aims: The Rutgeerts' scoring system is used to evaluate patients with Crohn's disease (CD) following ileocolic resection, based on endoscopic findings at the anastomosis and in the neoterminal...
2.
Lewis J, Rutgeerts P, Feagan B, DHaens G, Danese S, Colombel J, et al.
Inflamm Bowel Dis
. 2019 Oct;
26(2):304-313.
PMID: 31644790
Background: The Crohn's Disease Activity Index (CDAI) has been criticized for being weakly correlated with bowel inflammation. We assessed correlation between Simple Endoscopic Score for Crohn's Disease (SES-CD) and individual...
3.
Ma C, Gecse K, Duijvestein M, Sandborn W, Zou G, Shackelton L, et al.
Clin Gastroenterol Hepatol
. 2019 Sep;
18(9):2139-2141.e2.
PMID: 31473359
Endoscopic evaluation for postoperative recurrence of Crohn's disease (CD) is routinely integrated into clinical practice. The Rutgeerts score (RS) was developed to grade the severity of endoscopic postoperative CD recurrence...
4.
Li K, Friedman J, Chan D, Pollack P, Yang F, Jacobstein D, et al.
Gastroenterology
. 2019 Jul;
157(4):1019-1031.e7.
PMID: 31279870
Background & Aims: Although ustekinumab is an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic manifestations of CD are unknown. Methods: We evaluated the...
5.
Hanauer S, Sandborn W, Feagan B, Gasink C, Jacobstein D, Zou B, et al.
J Crohns Colitis
. 2019 Jun;
14(1):23-32.
PMID: 31158271
Background And Aims: Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn's disease, patients entered a long-term extension for up to 5 years from induction. Efficacy through 152...
6.
Yang L, Tang S, Baker S, Arijs I, Liu W, Alkhouri R, et al.
Inflamm Bowel Dis
. 2019 Apr;
25(11):e154.
PMID: 30958546
No abstract available.
7.
Philip G, Cornillie F, Adedokun J, Melsheimer R, Rutgeerts P, Colombel J, et al.
J Crohns Colitis
. 2019 Mar;
13(10):1257-1264.
PMID: 30847474
Background And Aims: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100-mg dose was used early in the course...
8.
Adedokun O, Gunn G, Leu J, Gargano C, Xu Z, Sandborn W, et al.
Inflamm Bowel Dis
. 2019 Feb;
25(9):1532-1540.
PMID: 30753466
Background: Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical...
9.
Panaccione R, Lofberg R, Rutgeerts P, Sandborn W, Schreiber S, Berg S, et al.
J Crohns Colitis
. 2019 Feb;
13(6):725-734.
PMID: 30753371
Background And Aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship...
10.
Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, et al.
J Crohns Colitis
. 2019 Jan;
13(7):916-930.
PMID: 30657881
Background And Aims: Early treatment of Crohn's disease [CD] is required in order to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular...